- Home
- ARQT vs UVV Comparison
ARQT vs UVV Comparison
Compare ARQT & UVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- UVV
- Stock Information
- Founded
- ARQT 2016
- UVV 1886
- Country
- ARQT United States
- UVV United States
- Employees
- ARQT N/A
- UVV N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- UVV Farming/Seeds/Milling
- Sector
- ARQT Health Care
- UVV Industrials
- Exchange
- ARQT Nasdaq
- UVV Nasdaq
- Market Cap
- ARQT 1.1B
- UVV 1.3B
- IPO Year
- ARQT 2020
- UVV N/A
- Fundamental
- Price
- ARQT $13.08
- UVV $51.72
- Analyst Decision
- ARQT Strong Buy
- UVV
- Analyst Count
- ARQT 5
- UVV 0
- Target Price
- ARQT $17.00
- UVV N/A
- AVG Volume (30 Days)
- ARQT 2.0M
- UVV 149.1K
- Earning Date
- ARQT 02-25-2025
- UVV 02-05-2025
- Dividend Yield
- ARQT N/A
- UVV 6.27%
- EPS Growth
- ARQT N/A
- UVV 5.05
- EPS
- ARQT N/A
- UVV 4.86
- Revenue
- ARQT $138,708,000.00
- UVV $2,827,901,000.00
- Revenue This Year
- ARQT $209.03
- UVV N/A
- Revenue Next Year
- ARQT $49.00
- UVV N/A
- P/E Ratio
- ARQT N/A
- UVV $10.50
- Revenue Growth
- ARQT 182.84
- UVV 6.40
- 52 Week Low
- ARQT $3.59
- UVV $45.19
- 52 Week High
- ARQT $16.20
- UVV $60.10
- Technical
- Relative Strength Index (RSI)
- ARQT 46.24
- UVV 41.19
- Support Level
- ARQT $12.61
- UVV $50.04
- Resistance Level
- ARQT $14.36
- UVV $50.94
- Average True Range (ATR)
- ARQT 0.98
- UVV 1.00
- MACD
- ARQT -0.32
- UVV -0.18
- Stochastic Oscillator
- ARQT 13.09
- UVV 36.83
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About UVV Universal Corporation
Universal Corp is a global leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segment includes Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States.